The medication Wegovy for obesity will not receive reimbursement
On Monday, 23 February, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) announced its decision. They have declined to subsidize Wegovy, which has quickly become one of the most discussed medications for obesity. Wegovy, which contains the now well‑known substance semaglutide, is used to help people with obesity lose weight. Novo Nordisk, the company behind the drug, had applied for it
https://www.arthritisportal.lu.se/article/medication-wegovy-obesity-will-not-receive-reimbursement - 2026-05-01
